BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 21,000 shares of Astria’s common stock on February 1, 2024 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were g
Business Wire Stock Sale/Buyback News